Emtricitabine/Tenofovir-DF (FTC/TDF, PrEP)
Quality of Evidence: Very Low
Coadministration with emtricitabine/tenofovir-DF has not been studied. Based on metabolism and clearance a pharmacokinetic interaction with emtricitabine is unlikely. Coadministration of tenofovir-DF (300 mg once daily) and lopinavir/ritonavir (400/100 mg twice daily) had no significant effect on lopinavir/ritonavir pharmacokinetic parameters; tenofovir AUC increased by 32%, Cmin increased by 51%, and there was no change in Cmax. A higher risk of renal impairment has been reported in patients receiving emtricitabine/tenofovir-DF and a ritonavir or cobicistat boosted protease inhibitor. No dose adjustment is recommended, but close monitoring of renal function and for tenofovir-associated adverse reactions is required.